Skip to content
DataLookout
Menu

NCT07602166

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 7 more changesShow less
    • Eligibility criteria expanded, about 29 words
    • Primary and study completion dates: Jul 2031 to Jul 31, 2031
    • Start date changed from estimate of Sep 2026 to Oct 30, 2026
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study description revised
    • Site details revised
    • Publications: details revised at 9 of 9 entries
  2. Notable Start date: Jul 2026 to Sep 2026
    • Collaborators expanded, about 5 words
    v3
  3. Minor Study description expanded, about 2 wordsv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in 24-hour ambulatory systolic blood pressure (SBP)
Timeframe: From week 0-4 and week 8-week12

Secondary (3)

FMD
Measurement of oxidative stress and inflammatory cytokines in blood and endothelial cells
Endothelial Cell Harvesting and Analysis

Arms and interventions

Arm 1: Drug-washout-placeboExperimental

Participants with salt sensitivity of blood pressure to receive treatment with 2-HOBA (500mg) three times a day for 4 weeks, followed by a washout period of 4 weeks, and then placebo for 4 weeks

Arm 2: Placebo-washout-DrugExperimental

Participants with salt sensitivity of blood pressure to receive treatment with placebo for 4 weeks followed by a washout period of 4 weeks, and then 2-HOBA (500mg) three times a day for 4 weeks.

Drugs: 2-hydroxybenzylamine, Placebo

Sites

1 site in 1 country

  • Vanderbilt University Medical CenterNashville, Tennessee, United States